News

Ozempic could help with his as a study by Goldman Sachs found that the mass-adoption of GLP-1 series drugs could allow for ...
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
WIPR ’s newly released UK Patents Rankings 2025 details the best of the UK market for patent work—from the firm that will ...
Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.
Our writer reveals what he thinks is the most exciting from the four investments he made in his Stocks and Shares ISA last ...
Investing.com -- AI-related stocks topped trading activity on Robinhood U.K. in June, led by Nvidia (NASDAQ: NVDA ), ...
Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...
A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, ...
The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like ...